Our goal is to transform the prevention and treatment of cancers and infectious diseases to significantly improve the lives of patients by developing and commercializing a new class of immunotherapeutics.
We are leveraging our modular arenavirus platform to develop the following product candidates for multiple cancers and infectious diseases - the efficacy of our replicating and non-replicating platforms is being tested all across our pipeline:
Single Vector LCMV
LCMV, PICV (2)
LCMV, PICV (3)
(1)ClinicalTrials.gov Identifier: NCT04180215; (2)Lymphocytic Choriomeningitis Virus; (3)Pichinde Virus; (4)PSA: Prostate-specific Antigen; PSMA: Prostate-specificMembrane Antigen; PAP: ProstaticAcid Phosphatase;(5)ClinicalTrials.gov Identifier: NCT03629080; (6)gB: GlycoproteinB; pp65: Tegument Protein 65. *2L, 2nd Line. **1L, 1st Line.